Source: prnewswire.com | Repost Duerson Fund 12/12/2022 –
Tesis Biosciences, the leader in targeted genetic sequencing, has announced a proposed study designed to develop molecular biomarkers to precisely differentiate mild traumatic brain injury (mTBI) from post-traumatic stress disorder (PTSD). Enabling a precise diagnosis can improve treatments for individuals who are susceptible for mTBI and PTSD such as U.S. military members and athletes as well as civilians of all ages.
The new study will use a high-throughput genomics approach to analyze peripheral blood mononuclear cells (PBMC) from mTBI-affected and non-TBI-affected veterans and civilians. The study will seek to identify complex changes in micro-RNA (miRNA) levels that may function as a sensitive and specific biomarker panel for mTBI. Each group in this cohort will also be matched for PTSD.
Tesis is preparing to apply for formal FDA approval of this panel, which will describe the research and development efforts to date as well as the scientific and technical merit and feasibility of a new concept or innovation that has the potential for development into new products, processes, or services.